MedTrace Logo

Study of UC-781 Vaginal Microbicide

NCT00132444 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2010-01-07

No results posted yet for this study

Summary

This study will help determine whether the agent UC-781, formulated as a gel, is safe when applied to the vagina twice daily for 14 days. It will also assess whether women find the gel acceptable to use.

Conditions

  • HIV Infections

Interventions

DRUG

topical vaginal application of UC-781 gel

UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days

Sponsors & Collaborators

Principal Investigators

  • Kimberly Workowski, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132444 on ClinicalTrials.gov